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Abstract: It has been suggested that the early detection of individuals
with prediabetes can help prevent cardiovascular diseases. The purpose
of the current study was to examine the cardiometabolic risk profile in
patients with prediabetes according to fasting plasma glucose (FPG)
and/or hemoglobin A1c (HbA1c) criteria.
Cross-sectional analysis from the 2022 patients in the Cohort study
in Primary Health Care on the Evolution of Patients with Prediabetes
(PREDAPS Study) was developed. Four glycemic status groups were
defined based on American Diabetes Association criteria. Information
about cardiovascular risk factors–body mass index, waist circumfer-
ence, blood pressure, cholesterol, triglycerides, uric acid, gamma-glu-
tamyltransferase, glomerular filtration–and metabolic syndrome
components were analyzed. Mean values of clinical and biochemical
characteristics and frequencies of metabolic syndrome were estimatedcational level, and family history of diabetes.
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Normoglycemic individuals had the best values, individuals with both
criteria of prediabetes had the worst, and individuals with only one–
HbA1c or FPG–criterion had an intermediate position. Metabolic
syndrome was present in 15.0% (95% confidence interval: 12.6–
17.4), 59.5% (54.0–64.9), 62.0% (56.0–68.0), and 76.2% (72.8–
79.6) of individuals classified in normoglycemia, isolated HbA1c,
isolated FPG, and both criteria groups, respectively.
In conclusion, individuals with prediabetes, especially those with
both criteria, have worse cardiometabolic risk profile than normogly-
cemic individuals. These results suggest the need to use both criteria in
the clinical practice to identify those individuals with the highest
cardiovascular risk, in order to offer them special attention with
intensive lifestyle intervention programs.
(Medicine 94(44):e1935)
Abbreviations: ADA = American Diabetes Association, FPG =
fasting plasma glucose, HbA1c = hemoglobin A1c, HDL
cholesterol = high-density lipoprotein cholesterol, IFG =
impaired fasting glucose, IGT = impaired glucose tolerance, LDL
cholesterol = low-density lipoprotein cholesterol, MDRD =
Modification of Diet in Renal Disease, PREDAPS Study =
Cohort study in Primary Health Care on the Evolution of Patients
with Prediabetes.
INTRODUCTION
P rediabetes is a term used to designate a condition associatedwith an increased risk of developing diabetes, which
includes an intermediate group of individuals whose blood
glucose levels are higher than normal, but do not reach the
cut-point values for diagnosing diabetes. The American Dia-
betes Association (ADA) recognize the following value ranges
to identify individuals with prediabetes: fasting plasma glucose
(FPG) levels from 100mg/dL (5.6mmol/L) to 125mg/dL
(6.9mmol/L), defined as impaired fasting glucose (IFG); 2-
hour values in the oral glucose tolerance test from 140mg/dL
(7.8mmol/L) to 199mg/dL (11.0mmol/L), defined as impaired
glucose tolerance (IGT); and hemoglobin A1c (HbA1c) from
5.7% to 6.4%.1
In addition to the high risk of diabetes, individuals with
prediabetes are at increased risk of developing cardiovascular
diseases.2,3 Also, a large percentage of these risk individuals
have the metabolic syndrome,4,5 a cluster of cardiovascular risk
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factors that also has been associated with diabetes and cardi-
ovascular diseases,6 and has been pointed as a clinical indicator
of macro and microvascular diabetes complications.7
There is evidence that each of the glycemic measures used
to identify prediabetes represents a different domain of glucose
metabolism. While FPG reflects basal disglycemia, HbA1c
reflects chronic exposure to basal and postprandial hypergly-
cemia.8 Also, it has been pointed that some characteristics, such
as sex, race, and age of individuals with prediabetes vary by
glycemic measure.9 Thus, there may be differences in the
cardiometabolic risk profiles of individuals according to the
glycemic measure used to evaluate the presence of prediabetes.
Several studies have been performed in nondiabetic indi-
viduals, searching for differences in cardiometabolic risk fac-
tors among IFG, IGT, and IFG-IGT groups.10–13 Comparing
groups formed on the basis of HbA1c and FPG criteria, how-
ever, are sparse.14 Therefore, our aim was to examine the
clinical and biochemical characteristics, and the prevalence
of metabolic syndrome components in patients grouped into
4 glycemic statuses according to HbA1c and FPG criteria
of prediabetes.
METHODS
Study Design and Populations
The Cohort study in Primary Health Care on the Evolution
of Patients with Prediabetes [Estudio de Cohortes en Atencio´n
Primaria sobre la evolucio´n de sujetos con prediabetes (PRE-
DAPS study)] is a follow-up study of a cohort of patients with
prediabetes and another cohort of patients without glucose
metabolism disorders. Complete information about the design
and methods of PREDAPS study have been previously
described.15 In summary, the study is being conducted by
general practitioners distributed across Spain, in the context
of their routine clinical practice. At the baseline stage, in 2012,
patients aged between 30 and 74 years old, whom consecutively
sought medical attention for any reason, were invited to partici-
pate in the study. Patients were excluded if they had diabetes,
terminal disease, pregnancy, surgery, or hospital admission in
the previous 3 months at study entry, or any hematologic
disease, which could alter HbA1c values. A total of 2022
patients gave their written informed consent for participation
in this study. The study was classified by the Spanish Agency of
Medicines and Medical Devices (Agencia Espan˜ola de Medi-
camentos y Productos Sanitarios) as a Non-Interventional
(Observational) Post-Authorization study, and the study proto-
col was approved by the Parc de Salut Mar Clinical Research
Ethics Committee in Barcelona.
According to criteria for categories of increased risk for
diabetes defined by ADA,1 patients were classified into 1 of 4
mutually exclusive groups of glycemic status on the basis of
plasma levels of HbA1c and FPG: 1) Normoglycemia group
(HbA1c< 5.7% and FPG< 100mg/dL), 2) Isolated HbA1c
group (HbA1c 5.7%–6.4% and FPG< 100mg/dL), 3) Isolated
FPG group (HbA1c< 5.7% and FPG 100–125mg/dL), and 4)
Both criteria group (HbA1c 5.7%–6.4% and FPG 100–
125mg/dL).
Measurements
Information about sociodemographic characteristics–age,
Gira´ldez-Garcı´a et alsex, educational level–and family history of diabetes was
obtained through questionnaire at baseline for all individuals.
The patients underwent physical examination to measure
2 | www.md-journal.comanthropometric parameters–height, weight, and waist circum-
ference–and blood pressure–3 readings–. Also, a blood sample
was obtained to determine plasma levels of the following
biochemical parameters: total cholesterol, high-density lipopro-
tein cholesterol (HDL cholesterol), triglycerides, uric acid,
gamma glutamyltransferase, hemoglobin, creatinine, FPG,
and HbA1c.
In this analysis, body mass index was calculated as weight
in kilograms divided by the square of height in meters. Systolic
and diastolic blood pressures were estimated by averaging of the
3 readings taken. Low-density lipoprotein cholesterol (LDL
cholesterol) was estimated by Friedewald equation.16 Glomer-
ular filtration was calculated using the abbreviatedModification
of Diet in Renal Disease (MDRD) equation.17
Metabolic syndrome was defined according to the 2009
harmonizing statement,18 although we also considered a value
of HbA1c 5.7% as criteria of elevated glycemia. Then, the
components of metabolic syndrome considered in this analysis
were defined as follows: elevated waist circumference
(102 cm in men or 88 cm in women), elevated triglycerides
(150mg/dL or drug treatment for elevated triglycerides),
reduced HDL cholesterol (<40mg/dL in men or <50mg/dL
in women, or drug treatment for reduced HDL cholesterol),
elevated blood pressure (systolic blood pressure 130mm Hg,
or diastolic blood pressure85mmHg, or antihipertensive drug
treatment in patients with history of hypertension), and elevated
glycemia (HbA1c 5.7%, or FPG 100mg/dL, or drug treat-
ment for elevated glycemia). Each measure involved in meta-
bolic syndrome definition was transformed into binary variables
to identify the presence or absence of each component, accord-
ing to cut points listed above. The presence of at least 3 of 5
components was considered as a diagnosis of metabolic
syndrome.
Statistical Analysis
Distribution of sociodemographic variables and family
history of diabetes according to study groups was compared
using the x2test. Then, for each glycemic status group, the mean
values of clinical and biochemical characteristics—adjusted for
age, sex, educational level, and family history of diabetes—
were estimated, and the differences in these values with respect
to the normoglycemia group were calculated. These analyzes
were performed by analysis of covariance. The adjusted fre-
quencies of metabolic syndrome and its components were
estimated using probit models. Finally, to know the number
of components in each group, the prevalence of patients with 0,
1, 2, 3, and 4 components of the metabolic syndrome was
estimated excluding the elevated glycemia component. Poly-
nomial contrasts were used for testing linear trends across
groups. P values <0.05 were considered as statistically signifi-
cant. Statistical analysis was performed using IBM SPSS
Statistics for Windows version 19 (IBM Corp, Armonk, NY).
RESULTS
A total of 838 participants (41.4%) were classified into
normoglycemia group, 316 (15.6%) into isolated HbA1c group,
254 (12.6%) into isolated FPG group, and 614 (30.4%) into both
criteria—HbA1c 5.7% to 6.4% and FPG 100 to 125mg/dL—
group.
Sociodemographic characteristics and family history of
Medicine  Volume 94, Number 44, November 2015diabetes according to the glycemic status are presented in
Table 1. Patients with both criteria of prediabetes were the
oldest, and they had the highest proportion of low educational
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Distribution of Sociodemographic Characteristics and Family History of Diabetes by Glycemic Status
Normoglycemia
Isolated HbA1c
5.7%–6.4%
Isolated FPG
100–125mg/dL
HbA1c
5.7%–6.4% and
FPG 100–125mg/dL P Value
N 838 316 254 614 —
Age, y
30–49 24.0 17.4 22.8 12.1 <0.001
50–64 48.9 48.7 50.8 49.8
65–74 27.1 33.9 26.4 38.1
Sex
Men 46.3 39.9 61.4 51.0 <0.001
Women 53.7 60.1 38.6 49.0
Educational level

Low 56.2 63.3 59.1 67.4 <0.001
High 43.8 36.7 40.9 32.6
Family history of diabetes
No 66.0 56.3 56.3 50.0 <0.001
Yes 34.0 43.7 43.7 50.0
Data are percentages. P values from the x2test for heterogeneity of proportions between the 4 categories of glycemic status. FPG¼ fasting plasma
glucose, HbA1c¼ hemoglobin A1c.
than
Medicine  Volume 94, Number 44, November 2015 Cardiometabolic Risk Profile and Prediabeteslevel and family history of diabetes. The proportion of men was
greater in the isolated FPG group, whereas the proportion of
women was greater in the isolated HbA1c group.
Means of clinical and biochemical characteristics adjusted
by age, sex, educational level, and family history of diabetes are
shown in Table 2 and mean differences with respect to nor-
moglycemia group are presented in Table 3. A linear trend was
observed in body mass index, waist circumference, systolic and
diastolic blood pressure, HDL cholesterol, triglycerides, uric
acid, and gamma glutamyltransferase values. The mean differ-
ences in these parameters showed the highest absolute value in

Low educational level: lower than secondary (equivalent to less
(equivalent to 12 years or more of education).the group with both criteria of prediabetes. In total cholesterol,
LDL cholesterol, hemoglobin, and glomerular filtration
parameters, no differences were found.
TABLE 2. Means of Clinical and Biochemical Characteristics by G
Clinical and Biochemical
Characteristics Normoglycemia
Isolated HbA1
5.7%–6.4%
Body mass index, kg/m2 27.42 28.89
Waist circumference, cm 93.64 97.75
Systolic blood pressure, mm Hg 128.87 132.35
Diastolic blood pressure, mm Hg 78.81 80.30
Total cholesterol, mg/dL 210.87 210.09
LDL cholesterol, mg/dL 129.58 130.81
HDL cholesterol, mg/dL 58.22 54.57
Triglycerides, mg/dL 114.70 124.39
Uric acid, mg/dL 5.07 5.31
Gamma glutamyltransferase, UI/L 29.10 32.20
Hemoglobin, g/dL 14.43 14.51
Glomerular filtration, mL/min/1.73m2 90.14 90.84
Data are adjusted by age, sex, educational level, and family history of diabe
of glycemic status. FPG¼ fasting plasma glucose, HbA1c¼ hemoglobin
cholesterol¼ low-density lipoprotein cholesterol.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Frequencies of each of the metabolic syndrome com-
ponents, adjusted for age, sex, educational level, and family
history of diabetes, are shown for the 4 glycemic status groups
in Table 4. The most prevalent component in all groups was
elevated blood pressure, followed by elevated waist circumfer-
ence. A progressive increase of frequency in all components
according to glycemic status was observed, such that the lowest
frequency was observed in the normoglycemia group, followed
by isolated HbA1c group, isolated FPG group, and the highest in
the both criteria group. The frequency of the metabolic syn-
drome as a whole was 15.0% in patients with normoglycemia,
12 years of education); high educational level: secondary or higher59.5% in patients with isolated HbA1c criterion, 62.0% in
patients with isolated FPG criterion, and 76.2% in patients with
both criteria of prediabetes. Because of the low prevalence in
lycemic Status, and P Values for Linear Trend
c Isolated FPG
100–125mg/dL
HbA1c 5.7%–6.4% and
FPG 100–125mg/dL
Linear
Trend P Value
29.01 30.70 <0.001
97.44 101.93 <0.001
134.15 134.90 <0.001
80.87 81.39 <0.001
208.96 209.29 0.396
129.73 127.88 0.317
54.93 53.96 <0.001
127.55 138.65 <0.001
5.47 5.70 <0.001
35.77 36.69 <0.001
14.57 14.45 0.507
89.72 91.25 0.530
tes.P values from polynomial contrast test that evaluates the linear effect
A1c, HDL cholesterol¼ high-density lipoprotein cholesterol, LDL
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TABLE 3. Adjusted Mean Differences (95% Confidence Intervals) in Clinical and Biochemical Characteristics According to
Glycemic Status
Clinical and Biochemical
Characteristics Normoglycemia
Isolated HbA1c
5.7%–6.4%
Isolated FPG
100–125 mg/dL
HbA1c 5.7%–6.4% and
FPG 100–125mg/dL
Body mass index, kg/m2 0 1.47 (0.87 to 2.07) 1.59 (0.94 to 2.24) 3.28 (2.79 to 3.77)
Waist circumference, cm 0 4.11 (2.63 to 5.59) 3.80 (2.19 to 5.41) 8.29 (7.07 to 9.50)
Systolic blood pressure, mm Hg 0 3.48 (1.51 to 5.45) 5.29 (3.15 to 7.42) 6.03 (4.42 to 7.64)
Diastolic blood pressure, mm Hg 0 1.49 (0.27 to 2.70) 2.05 (0.73 to 3.38) 2.58 (1.58 to 3.57)
Total cholesterol, mg/dL 0 0.78 (5.67 to 4.11) 1.90 (7.21 to 3.41) 1.58 (5.58 to 2.43)
LDL cholesterol, mg/dL 0 1.23 (3.16 to 5.61) 0.15 (4.60 to 4.89) 1.70 (5.27 to 1.88)
HDL cholesterol, mg/dL 0 3.66 (5.48 to 1.84) 3.29 (5.26 to 1.33) 4.26 (5.75 to 2.78)
Triglycerides, mg/dL 0 9.69 (0.62 to 18.76) 12.86 (3.00 to 22.71) 23.95 (16.51 to 31.39)
Uric acid, mg/dL 0 0.24 (0.08 to 0.40) 0.40 (0.23 to 0.57) 0.62 (0.49 to 0.75)
Gamma glutamyltransferase, UI/L 0 3.10 (1.20 to 7.39) 6.67 (2.06 to 1.27) 7.59 (4.09 to 11.08)
Hemoglobin, g/dL 0 0.08 (0.06 to 0.22) 0.14 (0.01 to 0.29) 0.02 (0.09 to 0.14)
Glomerular filtration, mL/min/1.73m2 0 0.71 (1.80 to 3.22) 0.42 (3.14 to 2.30) 1.12 (0.94 to 3.18)
f dia
w-d
Gira´ldez-Garcı´a et al Medicine  Volume 94, Number 44, November 2015normoglycemic patients with respect to the other groups, the
trend in the magnitude of the prevalence over the 4 groups was
deviated from linearity.
The distribution of the number of components present—
excluding elevated glycemia component—for each glycemic
status group is showed in the Figure 1. It can be seen that the
percentage of individuals with either 0 or 1 component is greater
in the normoglycemia group, whereas the percentage of indi-
viduals with 2, 3, or 4 components is greater in the group with
both criteria of prediabetes. The percentages of patients who did
not meet any component of metabolic syndrome were 21% in
individuals with normoglycemia, 11% in those with isolated
HbA1c criterion, 8% in those with isolated FPG criterion, and
Data are adjusted by age, sex, educational level, and family history o
cholesterol¼ high-density lipoprotein cholesterol, LDL cholesterol¼ lo5% in those with both criteria. On the other end of the
distribution, patients who meet 4 components, the percentages
were 3%, 7%, 7%, and 11%, respectively.
DISCUSSION
Individuals with prediabetes defined by both HbA1c and
FPG criteria had the worst values in clinical and biochemical
characteristics related to increase cardiovascular risk, and the
highest frequency of metabolic syndrome. On the other hand,
individuals with prediabetes defined by only one—HbA1c or
TABLE 4. Frequencies of Metabolic Syndrome Components by G
Normoglycemia
Isolated HbA1c
5.7%–6.4%
Elevated waist circumference 43.6 (40.1–47.0) 59.8 (54.3–65.4)
Elevated triglycerides 20.6 (17.8–23.4) 23.8 (19.0–28.6)
Reduced HDL cholesterol 15.4 (12.9–17.9) 22.5 (17.8–27.2)
Elevated blood pressure 62.8 (59.4–66.2) 71.0 (65.9–76.1)
Metabolic syndrome 15.0 (12.6–17.4) 59.5 (54.0–64.9)
Data are percentages (95% confidence intervals) adjusted by age, sex, edu
contrast test that evaluates the linear effect of glycemic status. FPG¼ fastin
density lipoprotein cholesterol.
In metabolic syndrome, the test for deviation from linearity was signifi
4 | www.md-journal.comFPG—criterion were at an intermediate cardiometabolic risk
profile, showing a more favorable profile than individuals with
2 criteria, but less favorable than individuals without any
criteria of prediabetes.
Results of comparisons of the 4 glycemic status groups
show that there are differences among groups in some of
characteristics examined. It is worth mentioning, differences
in sex distribution observed in prediabetic groups, where the
proportion of men was greater in the isolated FPG group and the
proportion of women was greater in the isolated HbA1c group.
Similar finding can be observed in other studies with prediabetic
groups defined by HbA1c and FPG criteria.19,20 Also, Lipska
et al21 have been pointed that women were more likely to be
identified with dysglycemia by HbA1c than FPG.
Studies comparing cardiometabolic risk measures in pre-
diabetes groups defined by FPG and IGT criteria have also
found in categories with any isolated criterion, an intermediate
risk profile between normoglycemic status—low risk—and the
combination of 2 criteria of prediabetes—high risk.10,11 More-
over, other studies based on nondiabetic individuals, which
have considered HbA1c and FPG as prediabetes criteria, had
betes. FPG¼ fasting plasma glucose, HbA1c¼ hemoglobin A1c, HDL
ensity lipoprotein cholesterol.observed higher levels of some cardiovascular risk factors in
individuals with prediabetes by both criteria.19,20 By contrast,
no differences in cardiometabolic risk profiles were observed by
lycemic Status, and P Values for Linear Trend
Isolated FPG
100–125mg/dL
HbA1c 5.7%–6.4% and
FPG 100–125mg/dL
Linear
Trend P Value
61.8 (55.7–67.8) 74.0 (70.4–77.6) <0.001
26.0 (20.6–31.4) 31.7 (27.9–35.4) <0.001
22.7 (17.5–28.0) 28.3 (24.6–31.9) <0.001
74.6 (69.1–80.1) 80.2 (76.9–83.5) <0.001
62.0 (56.0–68.0) 76.2 (72.8–79.6) <0.001

cational level, and family history of diabetes. P values from polynomial
g plasma glucose, HbA1c¼ hemoglobin A1c, HDL cholesterol¼ high-
cant, because the model that best fit the data was the quadratic model.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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36%
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prediabetes based on the same criteria. The fact that having at
least 1 cardiometabolic risk factor was a criterion to include
participants in their study could explain this inconsistency,
because their study groups were more homogeneous respect
to baseline risk.
There is sufficient evidence that metabolic syndrome is
strongly related with hyperglycemia.4,5,22 As expected, we
found a high percentage of metabolic syndrome in individuals
with prediabetes. A higher prevalence of this syndrome in
individuals with both criteria of prediabetes than in those with
only one criterion has been reported.5,10 In our study, apart
from the frequency of metabolic syndrome as a whole, the
percentage of individuals in normoglycemia group who had
no metabolic syndrome components present was 4 times
higher than the corresponding percentage in both criteria
group. While the percentage of individuals in normoglycemia
group who met the 4 metabolic syndrome components was
less (approximately half) than the corresponding percentage
FIGURE 1. Percentages of each number of metabolic syndrom
component) in each glycemic status group.of individuals in isolated criterion groups, and even less
(approximately one-third) compared with the same in the
both criteria group. This is consistent with the other findings
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.of this study, the cardiometabolic risk increases according to
the number of prediabetes criteria present increases.
The worst risk profile observed in individuals with both
criteria of prediabetes could be explained by the differences in
the role of FPG or HbA1c to detect glucose metabolism
disorders. If each measure represents a different pathophysio-
logic mechanism, it can be expected that individuals with both
criteria of prediabetes have a higher risk than those with only
one criterion.
Compared with individuals in the isolated FPG group, it is
noteworthy that those in the isolated HbA1c group had slightly
lower values in the most of clinical and biochemical parameters
related to cardiovascular risk. In this sense, Heianza et al20 have
pointed a similar finding: individuals diagnosed by isolated
HbA1c criterion were more likely to have lower values in body
mass index, blood pressure, and serum concentrations of tri-
glyceride, HDL cholesterol, uric acid, and gamma glutamyl-
transferase. The above results could be indicative of a lower
cardiovascular risk profile in individuals with isolated HbA1c
omponents present (excluding the ‘‘elevated plasma glucose’’criterion at diagnosis of prediabetes. We, however, must not
overlook that more favorable waist circumference and HDL
cholesterol values were observed in the isolated FPG group.
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Moreover, there are discrepancies in findings across studies. For
example, Saukkoken et al23 reported higher mean values of
body mass index and triglycerides in the isolated HbA1c group
compared with isolated FPG group, and not differences in blood
pressure and waist circumference between both groups. And
other authors have also reported contradictory results, for some
parameters slightly lower values were observed in HbA1c
group, and for others in FPG group.14,19
In a recent study conducted in middle-aged Caucasian-
Europeans, it can be observed that the subjects classified as
prediabetic using HbA1c criterion has lower body mass index,
waist circumference, and triglycerides levels and higher
HDL cholesterol than those subjects classified using FPG
criterion.24 In this study, when we analyzed waist circumfer-
ence and HDL cholesterol parameters using metabolic
syndrome components cut points, we also observed that fre-
quencies of these criteria were lower in isolated HbA1c group
than isolated FPG group. The same has been seen for elevated
triglycerides and elevated blood pressure criteria, and meta-
bolic syndrome as awhole. This finding is consistent with those
studies on prevalence of metabolic syndrome comparing
HbA1c criterion of elevated glycemia with FPG criterion,
where the prevalence was lower when alone HbA1c criterion
was considered to determine the presence of syndrome.25–27
However, in the only one study that shows results of metabolic
syndrome components, the frequencies of elevated waist cir-
cumference and reduced HDL cholesterol were higher in the
group based on HbA1c criterion than in the group based on
FPG.25 On the other hand, higher FPG levels rather than higher
HbA1c levels have been more strongly associated with an
increased risk for development of hypertension at 5 years
among Japanese.28
Then, several hypotheses can be proposed about the pre-
sence of isolated HbA1c criterion at prediabetes diagnosis. First
of all, it identifies individuals with a slightly lower metabolic
risk status compared with those detected by isolated FPG
criterion. Second, it identifies individuals with a risk status
related to a very early stage of cardiovascular disease. And
finally, it cannot be ruled out that isolated HbA1c criterion is
more specific to identify those characteristics, which are more
strongly related to cardiovascular diseases, such as low HDL
cholesterol and high waist circumference.
This study is being carried out in routine clinical practice
and includes a large number of individuals across nationwide,
which are being followed annually. Despite this strength, all
patients studied are primary health care users, and the frequency
of cardiometabolic risk factors could be different from other
settings or from the general population. So care should be taken
in generalizing these results.
This study had some limitations. First, patients were
classified into groups based on single measurements of HbA1c
and FPG, and so we cannot rule out the possibility of mis-
classification bias because of potential problems with intrain-
dividual variability of glycemia measures.29 Second, a level of
HbA1c 5.7% was considered as an additional criterion of
elevated glycemia component of metabolic syndrome, which is
not included in current definitions of this syndrome. We,
however, calculated the frequencies of metabolic syndrome
excluding the elevated glycemia component (data not shown)
and the results were very similar to those observed when this
component was included. This finding support the use of the
Gira´ldez-Garcı´a et alHbA1c levels in range of prediabetes as an additional measure
to screen glycemic component of metabolic syndrome, an issue
that has been pointed by some authors.25,30
6 | www.md-journal.comIn conclusion, individuals with prediabetes have a
worse cardiometabolic risk profile than normoglycemic indi-
viduals, and those with both criteria of prediabetes have the
worst risk profile. These results suggest the need to use both
criteria in the clinical practice to identify those individuals
with the highest cardiovascular risk in order to offer them
special attention with intensive lifestyle intervention pro-
grams. Some of our findings suggest that individuals with
isolated HbA1c criterion at diagnosis of prediabetes might
Medicine  Volume 94, Number 44, November 2015have a slightly lower cardiometabolic risk than those with
isolated FPG criterion, but further studies are needed on
this topic.
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